DexCom, Inc. - DXCM STOCK NEWS

The Alberta Government now covers the Dexcom G7 Continuous Glucose Monitoring (CGM) System for eligible residents with type 1 or type 2 diabetes. Dexcom G7 has been added to the Alberta Drug Benefit List, expanding eligibility to include adults aged 18 and older. Residents under 18 must require ongoing insulin or insulin pump therapy, while those 18 and older must use an insulin pump, basal and bolus insulin, or premixed insulin. Dexcom G7 is designed to simplify diabetes management and lower A1C levels. The system offers features like quick sensor warm-up, predictive Urgent Low Soon alerts, and compatibility with various digital health apps. This move aligns Alberta with other Canadian regions, enhancing access to CGM technology. For more information, visit Dexcom's website.

Dexcom (NASDAQ:DXCM) and ŌURA have announced a strategic partnership to integrate Dexcom's glucose biosensor data with ŌURA's health metrics. The partnership includes a $75 million strategic investment from Dexcom in ŌURA's Series D funding, valuing ŌURA at over $5 billion. The companies will enable two-way data flow between their products and launch co-marketing efforts.

The first app integration is expected in the first half of 2025. ŌURA reported selling 2.5 million rings and expects to double annual sales to approximately $500 million in 2024. The partnership aims to provide users with comprehensive metabolic health management by combining glucose data with sleep, stress, heart health, and activity metrics.

Dexcom launches a global campaign for World Diabetes Day, revealing that nearly 70% of people with diabetes struggled to start their health journey post-diagnosis, and almost half felt in pursuing their passions. The company's survey across multiple countries shows 85% of respondents believe small steps in diabetes management lead to significant wellbeing improvements, while 84% of tech users affirm that CGM technology helps achieve their dreams. Dexcom is partnering with brand advocates and celebrities to encourage diabetics to share their aspirations on social media, offering a $500 giveaway in the U.S. to help winners start their journey.

DexCom (DXCM) reported Q3 2024 financial results with revenue growing 2% year-over-year to $994.2 million. U.S. revenue declined 2% while international revenue grew 12%. GAAP operating income was $152.0 million (15.3% of revenue), showing a 580 basis points decrease compared to Q3 2023. The company launched Stelo, the first over-the-counter glucose biosensor in the U.S. for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom reiterated its 2024 guidance with expected revenue of $4.00-4.05 billion and announced the retirement of Chief Commercial Officer Teri Lawver at year-end.

DexCom, Inc. (NASDAQ:DXCM) has announced its plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. The company will hold a conference call and webcast to review the Q3 2024 performance starting at 4:30 p.m. Eastern Time on the same day.

Investors and interested parties can access the webcast link on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference. To participate in the conference call, attendees should dial (877) 344-3040 (US/Canada) or (646) 475-1647 (International) and use the confirmation ID "9430114" approximately five minutes before the start time.

Dexcom, Beyond Type 2, and actress Retta are establishing National Glucose Awareness Week from Sept. 23-29, 2024. This initiative aims to close the glucose knowledge gap and encourage people to take action on their glucose health. The week will feature educational resources about glucose health and information on new glucose biosensing technology.

A recent survey found that only 10% of people with Type 2 diabetes or prediabetes understand factors affecting their glucose levels well. The initiative includes a nationwide step challenge and opportunities to win prizes while learning about glucose health. Retta, who manages Type 2 diabetes, will inspire others to get involved.

The campaign targets not only those diagnosed with diabetes or prediabetes but also aims to raise awareness among the general population, as one-third of the U.S. population has diabetes or prediabetes, with many unaware of their condition.

Dexcom (NASDAQ: DXCM) has launched the third season of Dexcom U, its NIL program for college athletes with diabetes. The 2024 roster includes 20 athletes across 12 sports from 18 colleges, all using Dexcom CGM technology. The program has expanded its mentorship initiatives, including the first-ever Dexcom U Sports Camp, bringing together professional athletes, Dexcom U members, and young athletes with diabetes.

Dexcom U aims to inspire and educate the diabetes community through representation and mentorship. The program provides free educational resources for athletes, parents, coaches, and teammates to better understand diabetes management in sports. Notable additions to the roster include Shelomi Sanders, a basketball player at Alabama A&M, highlighting the program's commitment to diverse representation in collegiate athletics.

Dexcom's G6 Continuous Glucose Monitoring (CGM) System is being used by astronauts on the Polaris Dawn mission to study the effects of spaceflight on human health, particularly glucose regulation. This marks a significant milestone for Dexcom (NASDAQ: DXCM) as the first use of their CGM technology in space. The mission will conduct about 40 scientific experiments over five days, exploring how microgravity and space conditions impact glucose health.

Dexcom is collaborating with Labfront to provide advanced analytics for the collected data. This research is important for understanding metabolic responses in space and ensuring space travel is inclusive for people with diabetes. The company recently launched Stelo, the first FDA-cleared glucose biosensor for non-prescription use by adults not using insulin, further expanding their portfolio of glucose monitoring solutions.

Dexcom (NASDAQ: DXCM) is set to showcase its Continuous Glucose Monitoring (CGM) technology at the EASD 2024 Conference Symposium. The event will feature expert panelists discussing the transformational effects of Dexcom CGM on clinical practice. Key highlights include:

1. Dexcom's position as the most experienced partner in Automatic Insulin Delivery (AID), powering more AID systems than any other CGM brand.

2. Studies showing Dexcom CGM's potential to support therapy de-escalation and optimize management in Type 2 diabetes.

3. Recent data indicating that 100% of Dexcom CGM users with Type 2 diabetes made dietary changes, and 91% felt empowered to manage their condition.

4. Evidence of long-term cost savings for healthcare systems across Europe.